NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
Location: United Kingdom, England, Cambridge
Total raised: $44.66M
Investors 5
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| 09.02.2024 | Neva SGR | nevasgr.co... |
| - | Club degli... | clubdeglin... |
| - | 3B Future ... | 3bfuturehe... |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.02.2024 | Series B | $12.17M | - |
| 19.01.2023 | Series B | $7.4M | - |
| 15.03.2021 | Series B | $21.13M | Claris Ven... |
| 16.11.2017 | - | $3.96M | - |
Mentions in press and media 12
| Date | Title | Description |
| 22.05.2024 | NeoPhore Closes Series B Extension Round | Neophore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised an undisclosed amount in Series B extension funding. Bristol Myers Squibb (NYSE: BMY) made the investment. The company intends to use the funds to exp... |
| 01.02.2024 | NeoPhore Raises Additional £9.6M in Series B Extension Financing | NeoPhore, a London, UK-based small molecule neoantigen immuno-oncology company, raised additional £9.6M in Series B funding. The round, which brought the total amount to £31.1M, saw participation from its existing syndicate, CPF managed by ... |
| 01.02.2024 | United Kingdom-based Neophore raises GBP 9.5 million in funding | London, United Kingdom-based small molecule neoantigen immuno-oncology company NeoPhore raised GBP 9.6 million (approx. USD 12.2 million) in a Series B extension. The round took place on January 31, 2023. Existing syndicates such as CPF, ma... |
| 19.01.2023 | NeoPhore Closes £6M Extension to Series B; Round to £21.5M | NeoPhore, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, raised £6M in an extension to its Series B funding, now totaling £21.5M. The investors included CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health ... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture M... |
| 15.03.2021 | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline | NeoPhore announces £15.2m financing to advance DNA mismatch repair pipeline 15-03-2021 NeoPhore Limited, a small molecule neoantigen immuno-oncology company, has announced the close of a £15.2m (US $21m) Series B round. The syndicate was le... |
| 12.03.2021 | NeoPhore: Cambridge startup secures £15M to develop advance drugs for treating cancer | NeoPhore is a Cambridge-based company focused on the discovery and development of novel molecule therapies to treat cancer. This is possible by stimulating the immune system. Now, the small molecule neoantigen immuno-oncology company has se... |
| 09.03.2021 | NeoPhore Closes £15.2M Series B Funding Round | NeoPhore Limited, a Cambridge, UK-based small molecule neoantigen immuno-oncology company, closed a £15.2m (US $21m) Series B funding round. The round was led by Claris Ventures with participation from 2Invest, 3B Future Health Fund and Ast... |
| 09.03.2021 | NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline | Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management |
| 16.11.2017 | NeoPhore Raises £3M in Funding | NeoPhore Ltd, a spin out from Cambridge, UK – based PhoreMost Ltd., focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system, raised £3m in funding. Sixth Element Ca... |
Show more